Neha Krishnamohan

Board Member

Neha Krishnamohan joined our board of directors in September 2022. Ms Krishnamohan has over 15 years of experience in healthcare investment banking and financial and strategic leadership. She most recently served as the chief financial officer and executive vice president of corporate development at Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers. Prior to that, she served as the chief financial officer and executive vice president of corporate development at Kinnate Biopharma Inc., a clinical-stage precision oncology company, where she led financial operations, business development, and investor relations and communications. She was also a leader on Kinnate’s exploration of strategic alternatives, which resulted in an asset sale to Pierre Fabre Laboratories and the sale of Kinnate to XOMA Corporation.

Prior to Kinnate, Ms Krishnamohan was a vice president in the healthcare investment banking group and a member of the mergers and acquisitions (M&A) group within the investment banking division at Goldman Sachs. While at Goldman Sachs, she worked with biopharmaceutical boards and management teams on strategic financial matters, including financings and M&A transactions, and was one of the lead bankers on Arcutis’ 2020 initial public offering. Ms Krishnamohan has successfully executed over $100 billion in transactions in the biopharmaceutical, medical technology, and tools/diagnostics sectors. She currently serves on the board of directors of Latigo Biotherapeutics and holds a BSE with a double major in biomedical engineering and economics from Duke University.